Comparative study of a reference PCR assay targeting kinetoplast DNA and a commercial kit targeting ribosomal DNA for the molecular diagnosis of visceral leishmaniasis
Quentin Andreotti, Eva Lemont, Nada Kuk, Mathilde Criado, Christophe Ravel, Yvon SterkersABSTRACT
Visceral leishmaniasis (VL) is a severe parasitic disease that requires accurate and timely diagnosis to prevent fatal outcomes. Molecular methods, particularly quantitative PCR (qPCR), have become central to VL diagnosis because of their high sensitivity and specificity. However, assay performance depends on several factors, including the choice of DNA target. We compared the analytical and clinical performance of an in-house reference qPCR targeting kinetoplast DNA with the Viasure
IMPORTANCE
Accurate diagnosis of visceral leishmaniasis (VL) is essential to prevent delayed treatment and fatal outcomes. Molecular assays have become central to diagnosis, but their performance varies with the genetic target used. This study shows that assays targeting kinetoplast DNA provide superior sensitivity compared to ribosomal DNA-based methods, particularly in cases with very low parasite burdens—a common scenario in clinical practice. The difference likely reflects the much higher copy number of kinetoplast DNA, which enhances detection when parasite levels approach the limit of detection. These findings underscore the need for assay developers to prioritize high-copy-number targets to ensure reliable diagnosis and effective monitoring of treatment response, reducing the risk of relapse and improving patient outcomes.